Literature DB >> 3871914

Phytohaemagglutinin activation of T cells through the sheep red blood cell receptor.

K O'Flynn, A M Krensky, P C Beverley, S J Burakoff, D C Linch.   

Abstract

Expression of receptors for sheep red blood cells and the ability to proliferate in response to phytohaemagglutinin (PHA) are the traditional properties of human T cells, but the function of the sheep red cell receptor (the T11 antigen) is controversial and the mechanism of PHA-induced mitogenesis unclear. Mitogenesis involves a complex series of cell-mediated and factor-dependent interactions, but a rise in intracellular free calcium concentration, [Ca2+]i, seems to be an important primary event in T-cell activation. We have now investigated the effects of three monoclonal antibodies, previously shown to inhibit mitogen-induced proliferation, on T-cell [Ca2+]i. We find that anti-LFA-2 and OKT11, which react with the sheep red cell receptor, have no effect on [Ca2+]i, nor do they inhibit the rise in [Ca2+]i induced by concanavalin A (Con A) or the mitogenic anti-T3 monoclonal antibody UCHT1 (ref. 11). They do, however, block PHA-induced Ca2+ mobilization. Anti-LFA-1, which reacts with the lymphocyte function-associated antigen, has no effect on intracellular Ca2+. These studies suggest that the sheep red blood cell receptor is an activation pathway for T cells and that the effects of PHA are mediated through this pathway.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3871914     DOI: 10.1038/313686a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  39 in total

1.  Expansion of activated human naïve T-cells precedes effector function.

Authors:  J M Brenchley; D C Douek; D R Ambrozak; M Chatterji; M R Betts; L S Davis; R A Koup
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

2.  Basis for defective responses of rheumatoid arthritis synovial fluid lymphocytes to anti-CD3 (T3) antibodies.

Authors:  M Lotz; C D Tsoukas; C A Robinson; C A Dinarello; D A Carson; J H Vaughan
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

3.  Different pathways of human T-cell activation revealed by PHA-P and PHA-M.

Authors:  K O'Flynn; M Russul-Saib; I Ando; D L Wallace; P C Beverley; A W Boylston; D C Linch
Journal:  Immunology       Date:  1986-01       Impact factor: 7.397

4.  Distinct patterns of transmembrane calcium flux and intracellular calcium mobilization after differentiation antigen cluster 2 (E rosette receptor) or 3 (T3) stimulation of human lymphocytes.

Authors:  C H June; J A Ledbetter; P S Rabinovitch; P J Martin; P G Beatty; J A Hansen
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

5.  In vitro OKT3-induced mitogenesis in selenium-deficient patients on a diet for phenylketonuria.

Authors:  R J Collins; P J Boyle; A E Clague; A E Barr; S C Latham
Journal:  Biol Trace Elem Res       Date:  1991-09       Impact factor: 3.738

6.  Differential sensitivity to cAMP among human cord and maternal/adult peripheral lymphocytes discloses differences between PHA- and OKT3-induced activation pathways.

Authors:  N Papadogiannakis; S A Johnsen; S Rosberg; R G Andersson; L B Olding
Journal:  Immunology       Date:  1989-11       Impact factor: 7.397

7.  Characterizing a soluble survival signal for activated lymphocytes from CD14+ cells.

Authors:  Xiaolei Tang; David E Yocum; David DeJonghe; Kathy Nordensson
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

8.  mRNA expression and RNA editing (2451 C-to-U) of IL-12 receptor beta2 in adult atopic patients.

Authors:  Eun Jin Kim; Won Mok Lee; Jung Sook Ha; Nam Hee Ryoo; Dong Suk Jeon; Jae Ryong Kim
Journal:  J Korean Med Sci       Date:  2006-12       Impact factor: 2.153

9.  Lipoic acid attenuates inflammation via cAMP and protein kinase A signaling.

Authors:  Sonemany Salinthone; Vijayshree Yadav; Robynn V Schillace; Dennis N Bourdette; Daniel W Carr
Journal:  PLoS One       Date:  2010-09-28       Impact factor: 3.240

10.  Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naïve and HSV-2-infected subjects.

Authors:  David M Koelle; Amalia Magaret; Christopher L McClurkan; Michael L Remington; Terri Warren; Florentina Teofilovici; Anna Wald
Journal:  Clin Vaccine Immunol       Date:  2008-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.